Introduction
Nexxana Desire is a prescription sexual-health treatment marketed for women experiencing low sexual desire. Unlike an over-the-counter supplement, it uses bremelanotide (PT-141), a prescription medication that acts on melanocortin receptors involved in sexual desire.
Nexxana connects customers with licensed providers and pharmacies. The company itself states that it is not a healthcare provider or pharmacy and does not prescribe or dispense medication.
The important question is whether bremelanotide works. Clinical trials show that it can increase sexual desire and reduce distress related to low desire in appropriately selected premenopausal women with hypoactive sexual desire disorder (HSDD).
Quick Summary Box
| Product | Nexxana Desire |
|---|---|
| Type | Prescription sexual-health treatment |
| Active Ingredient | Bremelanotide (PT-141) |
| Target Condition | Acquired, generalized HSDD in premenopausal women |
| Administration | Subcutaneous injection |
| Use | As needed before anticipated sexual activity |
| FDA-Approved Ingredient | Yes — bremelanotide is FDA-approved as Vyleesi for the specified HSDD indication |
| Product-Specific Trial | No Nexxana-specific clinical trial identified |
What Is Nexxana Desire?
Nexxana Desire is a provider-guided treatment program centered on bremelanotide. Nexxana says customers complete a health intake that is reviewed by a licensed U.S. provider, and prescriptions are filled through licensed compounding pharmacies when appropriate.
Bremelanotide itself is not experimental. The FDA approved Vyleesi (bremelanotide injection) in 2019 for premenopausal women with acquired, generalized HSDD that causes significant distress and is not explained by another medical or psychiatric condition, relationship problems, or medication effects.
That distinction is important: Nexxana is a service/platform, while bremelanotide is the active prescription treatment.
How Does Nexxana Desire Work?
Bremelanotide activates melanocortin receptors, particularly MC4 receptors, in the brain. This pathway is involved in sexual motivation and desire.
In two Phase 3 randomized, placebo-controlled trials involving more than 1,200 women, bremelanotide produced statistically significant improvements in sexual desire and reductions in distress associated with low desire compared with placebo.
The treatment is used on demand rather than as a daily medication. FDA labeling specifies 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than eight doses per month.
Nexxana Desire Key Ingredient
Bremelanotide (PT-141)
Bremelanotide is a melanocortin receptor agonist specifically studied for female sexual dysfunction and HSDD.
A Phase 3 trial program found that women receiving bremelanotide experienced greater improvements in sexual desire and reduced distress compared with placebo. Common adverse effects included nausea, flushing, and headache.
A separate randomized dose-finding study also found improvements in sexual-function measures among premenopausal women with female sexual dysfunction.
Study links:
Bremelanotide Phase 3 Trials – PubMed
Bremelanotide Dose-Finding Trial – PubMed
FDA Approval Information for Vyleesi
Nexxana Desire Benefits
Based on the clinical evidence for bremelanotide, the treatment may:
- Increase sexual desire in appropriately diagnosed premenopausal women with HSDD.
- Reduce distress associated with low sexual desire.
- Activate brain pathways involved in sexual motivation.
- Provide an on-demand treatment option rather than daily dosing.
- Offer provider involvement through Nexxana’s treatment process.
These benefits apply to the appropriate patient population studied in clinical trials. They should not be generalized to every woman experiencing low libido.
Nexxana Desire Pros & Cons
Pros
- Uses an FDA-approved active medication for its established indication.
- Supported by randomized Phase 3 clinical trials.
- Designed for on-demand use.
- Provider review is part of the Nexxana process.
- Discreet delivery is advertised.
Cons
- Requires prescription approval.
- Not indicated for postmenopausal women or men.
- Not intended simply to enhance sexual performance.
- Nausea, flushing, and headache are common adverse effects.
- Contraindicated in uncontrolled hypertension or known cardiovascular disease.
- Nexxana itself does not conduct the prescribing or pharmacy dispensing.
Comparison Table with Alternatives
| Option | Primary Use | Key Difference |
|---|---|---|
| Nexxana Desire / Bremelanotide | HSDD in premenopausal women | On-demand melanocortin receptor treatment |
| Flibanserin | HSDD in certain women | Daily oral treatment |
| Sexual-health counseling | Desire, relationship, psychological factors | Non-drug approach |
| Medical evaluation | Identify underlying causes | Can address medication, hormonal, medical, or psychological contributors |
The FDA notes that bremelanotide is specifically indicated for acquired, generalized HSDD in premenopausal women and is not approved to enhance sexual performance.
Customer Reviews
Nexxana’s marketing materials emphasize provider support, discreet delivery, and convenience. Third-party websites also publish positive testimonials, but these should be treated as anecdotal rather than clinical evidence.
The more useful evidence comes from the randomized clinical trials of bremelanotide. Those studies provide controlled comparisons between bremelanotide and placebo rather than relying on customer testimonials.
Who Should Consider Nexxana Desire?
Nexxana Desire may be relevant to premenopausal women with acquired, generalized HSDD when low sexual desire causes significant distress and is not explained by another condition, relationship issue, or medication.
A licensed healthcare provider should determine whether the treatment is appropriate.
Who Should Avoid It?
According to FDA prescribing information, bremelanotide should not be used by women with uncontrolled hypertension or known cardiovascular disease. It is also not indicated for postmenopausal women or men.
Anyone with persistent changes in sexual desire should also discuss possible causes with a healthcare professional before starting treatment.
Side Effects & Safety
The most common adverse effect is nausea. FDA information also identifies temporary increases in blood pressure and decreases in heart rate after dosing.
Other important considerations include:
- Nausea: Can be significant in some users and may require treatment.
- Flushing: Reported commonly in clinical trials.
- Headache: Another frequently reported adverse effect.
- Blood pressure: Bremelanotide can temporarily increase blood pressure.
- Hyperpigmentation: Repeated use has been associated with focal skin or gum pigmentation.
Because this is a prescription medication, the prescribing clinician should review cardiovascular history, medications, and other contraindications before treatment.
Pricing & Packages
Current Nexxana materials advertise three program options:
| Plan | Displayed Price | Provider Check-Ins |
|---|---|---|
| 3 Months | $199/month | 1 |
| 6 Months | $179/month | 2 |
| 12 Months | $159/month | 4 |
These prices are presented as program pricing and may include provider and pharmacy-related services. Pricing can change, so the checkout page should be reviewed before ordering.
Frequently Asked Questions
1. What is Nexxana Desire?
Nexxana Desire is a provider-guided treatment program centered on prescription bremelanotide for appropriate women with low sexual desire.
2. What is the active ingredient?
The active medication is bremelanotide, also known as PT-141.
3. Does bremelanotide actually work?
Phase 3 randomized trials found statistically significant improvements in sexual desire and reductions in distress compared with placebo in premenopausal women with HSDD.
4. Is Nexxana Desire FDA approved?
Nexxana itself is not an FDA-approved drug. Bremelanotide is FDA-approved under the brand Vyleesi for a specific HSDD indication.
5. Is Nexxana Desire a supplement?
No. Nexxana Desire is presented as a prescription treatment program rather than a dietary supplement.
6. How is bremelanotide administered?
FDA labeling specifies subcutaneous injection into the abdomen or thigh.
7. How long before intimacy is it taken?
The FDA-approved dosing instructions specify at least 45 minutes before anticipated sexual activity.
8. Can postmenopausal women use bremelanotide?
Bremelanotide is not FDA-indicated for HSDD in postmenopausal women.
9. What are the main side effects?
Nausea, flushing, and headache are among the most commonly reported adverse effects. Temporary blood-pressure increases can also occur.
10. Can Nexxana Desire be used simply to increase sexual performance?
No. FDA labeling specifically states that bremelanotide is not indicated for enhancing sexual performance.
Final Verdict
Nexxana Desire is different from the typical female sexual-wellness supplement. Its central treatment, bremelanotide, is a prescription medication with randomized Phase 3 evidence supporting its use for acquired, generalized HSDD in appropriately selected premenopausal women.
The strongest evidence is therefore for bremelanotide itself, not for Nexxana as an independently studied treatment platform.
Nexxana’s main role is connecting users with licensed providers and pharmacies. The company states that it does not prescribe or dispense medication itself.
Editorial assessment: Nexxana Desire may be a legitimate option for women who meet the medical criteria for bremelanotide treatment, but it is not appropriate for everyone with low libido. Cardiovascular history, blood pressure, menopausal status, medications, and the underlying reason for reduced desire all matter.
For anyone experiencing persistent low sexual desire, a medical evaluation is important because sexual symptoms can have medical, psychological, relationship, or medication-related causes.
Our Top Female Libido, Sexual Arousal & Menopause Support Products
We evaluated these products based on key factors relevant to their intended use. Our editorial ratings consider ingredient transparency, available scientific evidence, formulation quality, safety considerations, value, and other product-specific factors.
Provestra
Product Type: Dietary Supplement
Primary Use: Female Libido & Menopause Support
Overall Rating: 4.9/5
Price: $59.00
Key Benefits
- Supports sexual desire and libido
- Supports vaginal lubrication
- Supports sexual sensitivity and satisfaction
- Supports menopause symptom management
Vigorelle
Product Type: Cream/Gel
Primary Use: Sexual Arousal, Lubrication & Sensitivity Support
Overall Rating: 4.8/5
Price: $59.00
Key Benefits
- Supports natural lubrication
- Supports sexual arousal and sensitivity
- Helps enhance sexual sensation
- Supports moisture and comfort
HerSolution
Product Type: Dietary Supplement
Primary Use: Female Libido, Arousal & Sexual Wellness Support
Overall Rating: 4.8/5
Price: $59.95
Key Benefits
- Supports sexual desire and libido
- Supports vaginal lubrication
- Supports sexual arousal and sensitivity
- Supports sexual satisfaction